PMID- 26893781
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 11
IP  - 2
DP  - 2016 Feb
TI  - Overexpression of ErbB2 renders breast cancer cells susceptible to 3-BrPA through 
      the increased dissociation of hexokinase II from mitochondrial outer membrane.
PG  - 1567-1573
AB  - ErbB2 is known to upregulate glycolysis in breast cancer, however, the precise 
      mechanisms remain unclear. In the present study, ErbB2 upregulated Hexokinase II 
      (HK II) activity by increasing the binding of HK II to the mitochondrial outer 
      membrane. Dysregulated glucose metabolism in high ErbB2-expressing breast cancer 
      cells induces susceptibility to glucose starvation and glycolysis inhibition. 
      Additionally, HK II has a tendency to dissociate from the mitochondria outer 
      membrane in ErbB2-overexpressing cells following treatment with the HK II 
      inhibitor, 3-BrPA. Furthermore, 3-BrPA treatment results in decreased 
      mitochondria membrane potential and release of cytochrome c into cytoplasm in 
      ErbB2-overexpressing cells, leading to activation of the mitochondrial apoptotic 
      signaling pathway. In summary, the results demonstrate a novel mechanism for 
      ErbB2-activated glycolysis and reveal that 3-BrPA is effective in reducing 
      ErbB2-positive breast cancer cell viability by targeting HK II in vitro and in 
      vivo.
FAU - Gao, Sujie
AU  - Gao S
AD  - Department of Anesthesiology, China-Japan Union Hospital, Jilin University, 
      Changchun, Jilin 130033, P.R. China; Central Research Laboratory, The Second 
      Hospital, Jilin University, Changchun, Jilin 130041, P.R. China.
FAU - Chen, Xuebo
AU  - Chen X
AD  - Department of General Surgery, China-Japan Union Hospital, Jilin University, 
      Changchun, Jilin 130033, P.R. China.
FAU - Jin, Hongyong
AU  - Jin H
AD  - Department of General Surgery, China-Japan Union Hospital, Jilin University, 
      Changchun, Jilin 130033, P.R. China.
FAU - Ren, Shengnan
AU  - Ren S
AD  - Department of General Surgery, China-Japan Union Hospital, Jilin University, 
      Changchun, Jilin 130033, P.R. China.
FAU - Liu, Zhuo
AU  - Liu Z
AD  - Department of General Surgery, China-Japan Union Hospital, Jilin University, 
      Changchun, Jilin 130033, P.R. China.
FAU - Fang, Xuedong
AU  - Fang X
AD  - Department of General Surgery, China-Japan Union Hospital, Jilin University, 
      Changchun, Jilin 130033, P.R. China.
FAU - Zhang, Guizhen
AU  - Zhang G
AD  - Central Research Laboratory, The Second Hospital, Jilin University, Changchun, 
      Jilin 130041, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20151221
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC4734279
OTO - NOTNLM
OT  - 3-BrPA
OT  - ErbB2
OT  - hexokinase II
EDAT- 2016/02/20 06:00
MHDA- 2016/02/20 06:01
PMCR- 2015/12/21
CRDT- 2016/02/20 06:00
PHST- 2014/11/06 00:00 [received]
PHST- 2015/07/16 00:00 [accepted]
PHST- 2016/02/20 06:00 [entrez]
PHST- 2016/02/20 06:00 [pubmed]
PHST- 2016/02/20 06:01 [medline]
PHST- 2015/12/21 00:00 [pmc-release]
AID - OL-0-0-4043 [pii]
AID - 10.3892/ol.2015.4043 [doi]
PST - ppublish
SO  - Oncol Lett. 2016 Feb;11(2):1567-1573. doi: 10.3892/ol.2015.4043. Epub 2015 Dec 
      21.